Webinar: Stabilizing scFv-Based Multispecifics

Watch the full expert session on how the Opti-mAb® technology can help address scFv instability, aggregation and expression challenges.

Multispecific antibodies often depend on scFvs that are elegant in design but difficult in practice. Instability, aggregation and poor expression slow down lead selection.

In this on-demand webinar, Julia Pizzolato PhD form evitria and Daniel X. Johansson PhD from AAX Biotech show how the Opti-mAb® technology addresses these developability risks at the design and optimization stage.

Webinar Insights Included:

  • scFv Stability: Why scFvs are unstable and how Opti-mAb® improves yield, aggregation and stability.
  • New Data on Complex Formats: Opti-mAb® tested in 3 complex asymmetric bi- and trispecific formats.
  • Side-by-Side Comparison: Original and Opti-mAb® versions compared on expression, purity and stability.
  • Expression Platform: How the technology works alongside evitria’s CHO-based platform.

Request the Webinar Recording!

Webinar Recording: Stabilizing scFv-Based Multispecifics
Name
Data protection